Insulin-like Growth Factor-I Concentration and Risk of Prostate Cancer: Results from the European Prospective Investigation into Cancer and Nutrition

Background: High circulating insulin-like growth factor-I (IGF-I) concentrations have been associated with increased risk for prostate cancer in several prospective epidemiological studies. In this study, we investigate the association between circulating IGF-I concentration and risk of prostate cancer over the long term in the European Prospective Investigation into Cancer and Nutrition (EPIC) study.

Methods: In a nested case-control design, 1,542 incident prostate cancer cases from eight European countries were individually matched to 1,542 controls by study center, age at recruitment, duration of follow-up, time of day, and duration of fasting at blood collection. Conditional logistic regression models were used to calculate risk for prostate cancer associated with IGF-I concentration, overall and by various subgroups.

Results: Circulating IGF-I concentration was associated with a significant increased risk for prostate cancer [OR for highest vs. lowest quartile, 1.69; 95% confidence interval (CI), 1.35-2.13; P(trend) = 0.0002]. This positive association did not differ according to duration of follow-up [ORs for highest vs. lowest quartile were 2.01 (1.35-2.99), 1.37 (0.94-2.00), and 1.80 (1.17-2.77) for cancers diagnosed <4, 4-7, and >7 years after blood collection, respectively (P(heterogeneity) = 0.77)] or by stage, grade, and age at diagnosis or age at blood collection (all subgroups P(heterogeneity) >0.05).

Conclusion: In this European population, high circulating IGF-I concentration is positively associated with risk for prostate cancer over the short and long term.

Impact: As IGF-I is the only potentially modifiable risk factor so far identified, research into the effects of reducing circulating IGF-I levels on subsequent prostate cancer risk is warranted.

Citing Articles

Curcumin inhibits growth and triggers apoptosis in human castration-resistant prostate cancer cells via IGF-1/PI3K/Akt pathway.

Chen C, Wang Q, Liu J J Int Med Res. 2025; 53(2):3000605231220807.

PMID: 39921429 PMC: 11806470. DOI: 10.1177/03000605231220807.

Dietary Pattern and Cancer.

Mumtaz S, Akhtar N, Ahmed A, Qazi A Cancer Treat Res. 2024; 191:191-216.

PMID: 39133409 DOI: 10.1007/978-3-031-55622-7_8.

Cognitive fusion-targeted biopsy versus transrectal ultrasonography-guided systematic biopsy: comparison and analysis of the risk of Gleason score upgrading.

Zheng T, Bi K, Tang Y, Zeng Y, Wang J, Yan L Int Urol Nephrol. 2023; 56(3):981-988.

PMID: 37875704 DOI: 10.1007/s11255-023-03848-y.

Effect of iron and calcium on radiation sensitivity in prostate cancer patients relative to controls.

Dhillon V, Deo P, Fenech M Mutagenesis. 2023; 38(6):305-314.

PMID: 37779442 PMC: 10728778. DOI: 10.1093/mutage/gead029.

Leptin: A Heavyweight Player in Obesity-Related Cancers.

Caruso A, Gelsomino L, Panza S, Accattatis F, Naimo G, Barone I Biomolecules. 2023; 13(7).

PMID: 37509120 PMC: 10377641. DOI: 10.3390/biom13071084.

References

Borugian M, Spinelli J, Sun Z, Kolonel L, Oakley-Girvan I, Pollak M . Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: a prospective multiethnic study. Cancer Epidemiol Biomarkers Prev. 2008; 17(1):252-4. DOI: 10.1158/1055-9965.EPI-07-2694. View

Holmes M, Pollak M, Willett W, Hankinson S . Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev. 2002; 11(9):852-61. View

Allen N, Key T, Appleby P, Travis R, Roddam A, Rinaldi S . Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev. 2007; 16(6):1121-7. DOI: 10.1158/1055-9965.EPI-06-1062. View

Gill J, Wilkens L, Pollak M, Stanczyk F, Kolonel L . Androgens, growth factors, and risk of prostate cancer: the Multiethnic Cohort. Prostate. 2010; 70(8):906-15. PMC: 2860643. DOI: 10.1002/pros.21125. View

Roddam A, Allen N, Appleby P, Key T, Ferrucci L, Carter H . Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med. 2008; 149(7):461-71, W83-8. PMC: 2584869. DOI: 10.7326/0003-4819-149-7-200810070-00006. View

Albertsen P, Hanley J, Barrows G, Penson D, Kowalczyk P, Sanders M . Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst. 2005; 97(17):1248-53. DOI: 10.1093/jnci/dji248. View

Epstein J, Allsbrook Jr W, Amin M, Egevad L . The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005; 29(9):1228-42. DOI: 10.1097/01.pas.0000173646.99337.b1. View

Yu H, Rohan T . Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000; 92(18):1472-89. DOI: 10.1093/jnci/92.18.1472. View

Kelley K, Oh Y, Gargosky S, Gucev Z, Matsumoto T, Hwa V . Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol. 1996; 28(6):619-37. DOI: 10.1016/1357-2725(96)00005-2. View

10.

Schmidt C . Gleason scoring system faces change and debate. J Natl Cancer Inst. 2009; 101(9):622-9. DOI: 10.1093/jnci/djp109. View

11.

Platz E, Pollak M, Rimm E, Majeed N, Tao Y, Willett W . Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. Cancer Epidemiol Biomarkers Prev. 1999; 8(12):1107-10. View

12.

Allen N, Appleby P, Davey G, Kaaks R, Rinaldi S, Key T . The associations of diet with serum insulin-like growth factor I and its main binding proteins in 292 women meat-eaters, vegetarians, and vegans. Cancer Epidemiol Biomarkers Prev. 2002; 11(11):1441-8. View

13.

Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, Biessy C, Dechaud H . Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst. 2000; 92(19):1592-600. DOI: 10.1093/jnci/92.19.1592. View

14.

Platz E, Pollak M, Leitzmann M, Stampfer M, Willett W, Giovannucci E . Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control. 2005; 16(3):255-62. DOI: 10.1007/s10552-004-3484-8. View

15.

Nimptsch K, Platz E, Pollak M, Kenfield S, Stampfer M, Willett W . Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the Health Professionals Follow-up Study 1993-2004. Int J Cancer. 2010; 128(3):660-7. PMC: 2948057. DOI: 10.1002/ijc.25381. View

16.

Crowe F, Key T, Allen N, Appleby P, Roddam A, Overvad K . The association between diet and serum concentrations of IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev. 2009; 18(5):1333-40. DOI: 10.1158/1055-9965.EPI-08-0781. View

17.

Pearce N . What does the odds ratio estimate in a case-control study?. Int J Epidemiol. 1993; 22(6):1189-92. DOI: 10.1093/ije/22.6.1189. View

18.

Etzioni R, Cha R, Feuer E, Davidov O . Asymptomatic incidence and duration of prostate cancer. Am J Epidemiol. 1998; 148(8):775-85. DOI: 10.1093/oxfordjournals.aje.a009698. View

19.

Chan J, Stampfer M, Ma J, Gann P, Gaziano J, Pollak M . Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst. 2002; 94(14):1099-106. DOI: 10.1093/jnci/94.14.1099. View

20.

Grimberg A . Mechanisms by which IGF-I may promote cancer. Cancer Biol Ther. 2003; 2(6):630-5. PMC: 4164051. View